To include your compound in the COVID-19 Resource Center, submit it here.

Medivir reports Phase IIa data of MIV-711 for OA

Medivir AB (SSE:MVIR B) reported top-line data showing that MIV-711 slowed the degenerative effects of moderate osteoarthritis (OA) on both bone and cartilage of the

Read the full 254 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE